Company Overview and News
Deutsche Bank Aktiengesellschaft’s (DB - Free Report) Chief Financial Officer, James von Moltke, hinted that third-quarter 2018 pretax profit is likely to be in line with the consensus estimate of €327 million, at an investor conference held in London.
DBFFF DB BNPQY NTB DBQZF DBWFF DBXFF DBCBW DBCQF ACA DBQFF DBFBF DBFMF DBAGF BNPQF CRARF DBZFF BNPZY DBWGF DBZQF DBYQF CRARY DBTMF DBWQF
Deutsche Bank Aktiengesellschaft (DB - Free Report) has been instructed by the German financial regulator — BaFin — to improve its processes aimed at preventing money laundering and terrorist financing. Also, the regulator has appointed a monitor whose duty would be to report and assess the progress of the ordered measures.
DBFFF DB NTB DBFMF HSNGF DBAGF DBZFF 0011 DBQZF DBWFF DBWGF DBXFF DBCBW DBCQF HSNGY DBZQF DBYQF DBQFF DBFBF DBTMF DBWQF
Deutsche Bank AG (DB - Free Report) has found a suitable buyer in Bank of Montreal (BMO - Free Report) for its $3 billion worth energy loan portfolio that includes investment-grade and subprime revolving credit lines to oil and gas companies. The news was reported by Bloomberg.
BMO DB HSNGY NTB BMO LB HSNGF 0011
Bringing in good news for shareholders, Britain-based Royal Bank of Scotland (RBS - Free Report) is expected to pay a special one-off dividend to shareholders using 4 billion pounds ($5.2 billion) of its surplus capital. The news was reported by the Times, following an interview with the bank's chairman Howard Davies. Per the source, Davies has the preference of using the idle cash for buying RBS shares from the government, however, the special dividend payment of 33 pence per share can be opted on shareholders’ demand.
HSNGY NTB DNBHF DNHBY
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Banco Macro S.A. (BMA - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
NTB BZH BZMD
Moody’s Corporation’s (MCO - Free Report) subsidiary, Moody’s Investors Service, has affirmed Banco Bilbao Vizcaya Argentaria, S.A.’s (BBVA - Free Report) ratings and outlook in its recent rating activity. While long-term deposit and senior unsecured debt ratings have been maintained at A2 and A3 respectively, baseline credit assessment (BCA) and adjusted BCA have been affirmed at baa2. Further, outlook has been maintained at ‘Stable’ for Banco Bilbao, as well as its subsidiaries (except its Turkish subsidiary).
NTB DNBHF NVMI DNHBY MCO BVA SMG
2018-08-29 sec.gov - 1
Bringing in good news for shareholders, Britain-based Royal Bank of Scotland (RBS - Free Report) came up with the first dividend announcement, along with its second-quarter 2018 earnings release, since its bailout by the Government in 2008. The move follows the bank’s aims to get its state stake reduced. Notably, the British government currently has a 62.4% stake in RBS which was taken up by paying 45.
BMO BCH NTB BMO BGSF FUN
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#(O2VED7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E M'0O M26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R P(# @-C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT
Document VIA EDGAR AND FEDERAL EXPRESS
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0S(# @;V)J#3P\+TQI;F5A
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NTB / Bank of N.T. Butterfield & Son Limited (The) on message board site Silicon Investor.
as of ET